Modern medicine increasingly targets treatments to patients whose biology suits them, guided by diagnostic tests. This precision-medicine revolution depends on getting the right patients tested and diagnosed, a complex challenge. Diaceutics (LSE:DXRX) provides data and services that help pharmaceutical companies do exactly that. As precision medicine expands, it could create a substantially bigger market for Diaceutics and its platform.
A precision-medicine data specialist
Diaceutics, listed on London’s AIM, provides Data Analytics and advisory services to pharmaceutical companies, helping them commercialise precision-medicine therapies. Many modern drugs work only for patients with specific biomarkers, so identifying and testing those patients is essential. Through its DXRX platform, Diaceutics gathers and analyses diagnostic testing data to help pharma clients understand testing patterns, find under-diagnosed patients and improve how their targeted therapies reach the right people, positioning it at the intersection of diagnostics, data and drug commercialisation.
The 2025 results
For the year to 31 December 2025, Diaceutics reported Revenue of about £38.4 million, up around 20%, or about 24% on a constant-currency basis, and returned to profitability with pre-tax profit of around £0.3 million. Adjusted EBITDA jumped about 80% to roughly £7.6 million. Annual Recurring Revenue rose about 19% to around £20 million, the order book reached a record of about £38.9 million, and net revenue retention was around 105%, with the number of customer therapeutic brands up about 12% to 95.
Why precision medicine expands the market
The growth of precision medicine directly enlarges Diaceutics’ opportunity. As more targeted therapies are developed and approved, pharma companies face the challenge of ensuring the right patients are tested and diagnosed to benefit from them. Each new precision therapy potentially needs the kind of diagnostic data and commercialisation support Diaceutics provides. With medicine shifting steadily towards biomarker-driven treatment across cancer and other diseases, the pool of therapies requiring such support keeps growing, expanding the addressable market for Diaceutics’ data and services over time.
Recurring revenue and deepening relationships
Diaceutics is building a more recurring, embedded business. Growing annual recurring revenue and a record order book point to increasingly predictable income, while net revenue retention above 100% shows existing clients spending more. It has expanded partnerships with major pharma companies and secured commercialisation partnerships tied to specific therapies, deepening its role in clients’ launches. By becoming a trusted data partner across more brands and moving towards recurring, platform-based revenue, Diaceutics can grow with its clients and the widening precision-medicine market.
The risks to weigh
Risks exist. Diaceutics depends on pharmaceutical companies’ spending and on the success and timing of their precision therapies, which it does not control. Revenue can be project-based and lumpy, though recurring revenue is growing. It relies on access to quality diagnostic data and on maintaining relationships with large clients, concentrating exposure. Competition and technological change, including in AI-driven analytics, are factors, and healthcare and regulatory shifts could affect demand. Converting a widening market opportunity into steady, profitable growth still requires consistent execution.
So why could the market grow bigger?
Precision medicine could create a bigger market for Diaceutics because every new biomarker-driven therapy needs the diagnostic data and commercialisation support it provides, and medicine is steadily moving that way, expanding its opportunity. The 2025 results, with rising revenue, a return to profit, growing recurring revenue and a record order book, show the Business strengthening. Client-dependency and execution risks are real. But as a specialist data partner in a growing field, Diaceutics is well placed to expand. Investors should watch recurring revenue, the order book and new pharma partnerships as the clearest measures of whether the market is genuinely widening for Diaceutics steadily over time.






Please wait processing your request...